ReviewJournal of the National Cancer Institute. Monographs2026
From evidence to action: the IARC's role in strengthening cancer prevention and early detection.
Review in Journal of the National Cancer Institute. Monographs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Prevention and early detection are central to reducing the global cancer burden, yet implementation remains uneven, particularly in low- and middle-income countries. This narrative review synthesizes the contributions of the International Agency for Research on Cancer (IARC) to translating evidence into policy and practice worldwide across vaccination, screening, and early diagnosis. Key advances include generating evidence that enabled the World Health Organization (WHO) recommendation of single-dose human papillomavirus vaccination; contributions to WHO Elimination of Cervical Cancer Initiative and Global Initiative on Breast Cancer; development of guidance for Helicobacter pylori screen-and-treat strategies; building decision platforms to optimize cost-effective strategies; and establishing CanScreen5 to benchmark cancer screening program performance globally. IARC led European Union screening status reports, codeveloped quality-assurance schemes, and standardized performance indicators. Through implementation research, capacity-building, and codesigned solutions, IARC supports prostate, gastric, and lung cancer screening pilots and equity-oriented approaches that strengthen health-care systems. By embedding evidence, modeling, and governance, IARC helps countries transition from pilots to population-level impact, accelerating progress toward WHO targets and equitable outcomes in cancer control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.